Omnio AB raises 5.5MSEK in fundraising round

SWEDEN, 6th December, 2021 - Omnio AB is developing new drug products based on the pro-inflammatory and immune regulatory effects of the serum protein plasminogen. During fall the company successfully raised 5.5MSEK in a new share issue and welcomed four new investors to the company. The added investments make it possible for the company to now initiate its planned activities to develop recombinant plasminogen for treatment of diabetic foot ulcers.

Omnio AB receives support from SweLife together with Umeå University and the county of Västerbotten to develop biological treatments for periodontitis and peri-implantitis

Omnio together with Umeå university and the county council selected by the Vinnova program SweLife receive support of a total of SEK 3 million to develop new treatments for periodontitis and peri-implantitis. In competition with 120 applications, 16 were selected that were considered to have the greatest potential to lead to future better health. Omnio's project was one of these.

Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted